A breast cancer survivor reflects on the complicated meaning of pink, remembering what cancer took, those still fighting and the people behind the ribbon.
|Articles|June 1, 2022
How Patients Can Navigate the BCG Shortage with Dr. Robert Svatek
Advertisement
In this episode of
- What BCG is and how it is used
- What the different strains are
- Why there is a BCG shortage
- What to do if your urologist doesn’t have BCG
- Alternatives to BCG
- The trial Dr. Svatek is doing about the Japanese strain
- The future of BCG treatments
Disclaimer: The views and opinions expressed in this podcast are those of the speakers and guests and do not necessarily reflect the views or positions of the Bladder Cancer Advocacy Network.
Advertisement
Related to this article
Paxalisib, first studied in brain cancer, may help HR+ breast tumors respond to CDK4/6 inhibitors again, based on early lab data.
A cancer survivor shares what to say, what not to say and how listening can help support someone through cancer treatment and beyond.
Bravnetsa is the first radioligand therapy approved through the FDA's abbreviated pathway, adding an option for adults with SSTR-positive GEP-NETs.
The investigational drug, first developed for brain cancer, is being tested to see whether it can make resistant tumors respond to treatment again.
Cancer research is increasingly looking beyond the tumor to understand the whole body, immune system and patient experience.
AI is becoming a growing part of cancer care. Learn how doctors are using it to navigate complex treatment decisions and support patients.
In patients with advanced ROS1-positive lung cancer who had not previously received a ROS1-targeted drug, Jideytro also shrank tumors that had spread to the brain in all 10 evaluable patients.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Bravnetsa, an Equivalent to Lutathera, for GEP-NETs
2
Finding the Words: How to Talk to Someone With Cancer
3
Cancer Research Is Looking Beyond the Tumor to Better Understand the Whole Patient
4
3 More Lung Cancer Breakthroughs From WCLC 2026
5